Interval cytoredutive surgery and HIPEC in advanced ovarian cancer with small-bowel disease: results and reflections

Campos, Pedro Antonio Cascales; Gil, Alida González; Gómez-Ruiz, Álvaro Jesús; Román, Andrés Balaguer; Gómez, Elena Gil; Alconchel, Felipe; Díaz, Aníbal Nieto; Valcárcel, Francisco Barceló; Martínez, José Gil

doi:10.1007/s12094-022-02795-x

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enhanced recovery after surgery is used postoperatively, and patients are cared for on the routine surgical floor. Other institutions have published guides to starting HIPEC protocols, most of which focus on perioperative care and considerations, as well as the multidisciplinary work needed to achieve a safe and efficacious HIPEC case [33–35,36 ▪ ,37–41].…”

Section: Perioperative Considerations When Administering Hyperthermic...mentioning

confidence: 99%

Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?

Praiss

Moukarzel

Zivanovic

2022

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Purpose of reviewOur objective is to provide a history, rationale, and review of the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of ovarian cancer.Recent findingsIn the last decade, there has been an increase in the literature regarding HIPEC in the treatment of ovarian cancer. The rationale for HIPEC extends from earlier trials demonstrating improved survival using intraperitoneal chemotherapy. HIPEC provides a one-time opportunity for intraperitoneal chemotherapy at the time of cytoreduction and with the addition of hyperthermia. Cisplatin HIPEC has been demonstrated to have a survival benefit when used in the interval cytoreductive setting. In terms of safety, nephroprotection remains a key concern when administering HIPEC. Sodium thiosulfate provides nephroprotection and should be considered when performing HIPEC. Various institutions have created multidisciplinary protocols for administering HIPEC, which include operating room staff, nursing, anesthesia, pharmacy, and surgical teams.SummaryHIPEC has a role in the treatment paradigm of ovarian cancer. Currently, HIPEC is approved in the interval cytoreductive surgery setting. Further trials are needed to understand the appropriate timing, chemotherapeutic agents, and protocolization of HIPEC.

show abstract

Section: Perioperative Considerations When Administering Hyperthermic...mentioning

confidence: 99%

Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?

Praiss

Moukarzel

Zivanovic

2022

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“… Small bowel involvement in patients with advanced ovarian cancer has been associated with a worse prognosis and recent data suggests it can be an independent factor associated with shorter disease-free interval ( Casales Campos et al, 2022 ). In the upfront cytoreductive setting, small bowel residual disease (serosa and mesentery) has been identified as the most common site of residual disease ( Heitz et al, 2016 ).…”

mentioning

confidence: 99%

“Mesenteric stripping using a Veress needle: A creative approach to resect small bowel disease in advanced ovarian cancer”

Casanova¹,

Cunha²,

Proença³

et al. 2023

Gynecologic Oncology Reports

View full text Add to dashboard Cite

Interval cytoredutive surgery and HIPEC in advanced ovarian cancer with small-bowel disease: results and reflections

Cited by 2 publications

References 21 publications

Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?

Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?

“Mesenteric stripping using a Veress needle: A creative approach to resect small bowel disease in advanced ovarian cancer”

Contact Info

Product

Resources

About